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but not acquainted on principles of STG. We conclude that MPs need repetitive in-
service training programs to ensure the adherence to STG and MSs are in need of
skill development programme to pertain STG in clinical practice.
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OBJECTIVES: The aim of this paper was to examine trends in expenditure of phar-
maceuticals on the community drug schemes from 2005 to 2010, during which time
a range of cost-containment interventions were introduced which affected the
pricing mechanism for pharmaceuticals in Ireland.METHODS:Data were analysed
using a national prescription claims database according to drug class, i.e. generic,
patent and off-patent for the two largest schemes; the General Medical Scheme
(GMS) and Drug Payment (DP) scheme. Segmented regression was used to analyse
the effects of the interventions on expenditure. RESULTS: An increase in expendi-
ture was noted across all schemes up to 2009 and declined thereafter to the end of
the study period (October 2010). Significant reductions in expenditure were noted
following the introduction of a 20% price-cut to patent-expired products (off-pat-
ents) (p0.001). In July 2009, pharmacy and wholesale margins were reduced, re-
sulting in significant reductions in expenditure for patented (GMS; p0.05 and DP
scheme; p0.001) and generic (DP scheme only; p0.01) products. No significant
reductions in expenditure were noted for off-patent products at this time. Further-
more, no significant reductions in expenditure were noted for off-patents following
a 15% price reduction in January 2009 and a further 40% price reduction in February
2010. CONCLUSIONS: Results from the study indicate that reductions in the whole-
sale margin and pharmacy mark-up had the largest impact on reducing pharma-
ceutical expenditure during the study period. This analysis of national expenditure
trends over a six-year period provides valuable information for the healthcare
payer on the impact of the cost-containment interventions and may provide a
benchmark for future negotiations with the pharmaceutical industry.
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OBJECTIVES: Health economic estimates of radioactivity-mediated diagnostic and
treatment procedures are seldom in literature. This would be the first one to com-
pare all these examinations and interventions in a large scale trial. Assessment of
costs matrix and prescribing patterns of radiology diagnostics and interventional
radiographics services and the roots of clinical decision making process contribut-
ing to unacceptable allocation of scarce hospital resources. METHODS: All inpa-
tients medical dossier files due to wide range of admission causes (approximately
50,000 per year) during three year term and their complete and accurate files on
imaging diagnostics and interventional radiographics procedures applied and their
consequent costs. An in depth retrospective bottom-up trend analysis of consump-
tion patterns and expenses relative to diagnosis at discharge conducted from per-
spective of Third party payer, for more than 200.000 inpatients of large tertiary care
university hospital (1200 beds) admitted from 2007-2009. RESULTS: There were
10.488 patients in 2007, 12.857 in 2008 and 11.893 in 2009 radiologically processed
patients with the total expense of provided services of €1,312,123 in 2007, €2,812,460
in 2008 and €1,829,764 in 2009. The patients cost on average 9.887 37.518 RSD (125
 475€) in 2007, 17.206  69.552 RSD (218  881€) in 2008 and 14.408  68.297 RSD
(154 731€) in 2009. On average, each patient got one lungs graph, each 7th got the
ultrasound of the abdomen, each 19th a CT check of the endocranium, whereas
each 25th patient got the NMR of the head. CONCLUSIONS: The obvious findings
confirm irrational prescribing of diagnostic procedures and necessities of cutting
costs. These consumption patterns noticed, should gave an important momentum
for policy-makers to intervene and provide higher guidelines adherence from cli-
nicians perspective.
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OBJECTIVES: To provide methodological and reporting guidelines for pharmaco-
economic evaluation (PE) for Serbia. METHODS: A group of researchers specialized
in economic evaluation of medicines developed the PE guidelines, following the
initiative of other countries in this framework, to provide recommendations for the
standardization of methodology applicable to economic evaluation of medicines in
Serbia. The guidelines were written in accordance with the best European and
international guidelines, with respect to the existing legislation in Serbia. Guide-
lines are based on a “reference case” (RC) which includes set of preferred methods
which analysts should follow when conducting PE for each component of the eco-
nomic evaluation. RESULTS: The literature review should be transparent and re-
producible. The RC analysis should only include direct health care costs from the
perspective of the health care payer, the governmental payer and the patient. The
study question should specify the target population(s) for the intervention. The
comparator to be considered in the evaluation is the treatment that most likely will
be replaced by the new treatment. Cost-effectiveness and cost-utility analyses are
accepted as reference case techniques, under specific conditions. Outcomes in PE
in terms of final endpoints instead of intermediary outcomes should be used in the
incremental cost-effectiveness ratio (ICER). For the calculation of quality-adjusted
life-years (QALYs), a generic quality-of-life measure should be used. Lifetime hori-
zon in principle in PE should be applied, shorter time horizons requires appropriate
justification. Uncertainty around the ICER should always be assessed. Costs and
outcomes should be discounted at 3% and 1.5%, respectively CONCLUSIONS: First
Serbian PE guidelines were developed as results of changes in Serbian health sys-
tem and the need for better and more complete economic information by decision
makers. By providing standards for conducting and reporting of economic evalua-
tions, guidelines can address current needs and requests of Serbian health care
system.
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OBJECTIVES: Price regulation for drugs is often justified by allegedly high profits of
the pharmaceutical industry. While older explanations emphasize the importance
of market-entry barriers and monopoly power, we argue that high profits are
mainly due to measurement errors that arise from the treatment of research and
development (R&D) investments and intangible capital by conventional account-
ing methods. Conventional accounting methods treat R&D as costs and not as an
investment that generates (intangible) capital. Applying accounting data for the
calculation of companies’ return on assets in turn leads to an upward bias of
profitability. In this paper we offer a method that corrects for this bias. Based on
financial data of 3382 firms worldwide we also estimate a corrected rate of return.
METHODS: Relying on financial data of 86 publicly listed pharmaceutical firms
between 1985 and 2004, we treated R&D expenditures as an investment which has
to be activated in the balance sheet. The assumed depreciation rate was 10%. We
then calculated the return on assets (i.e. profits after depreciation of intangibles/
total assets including intangible capital) and compared the corrected returns with
that of 3296 firms of 34 other industries. RESULTS: We show that corrected profit
rates of the pharmaceutical industry drop by three (average) to five (median) per-
centage points when assets are calculated to include intangible R&D capital. While
the uncorrected profitability of the pharmaceutical industry is indeed among the
highest of all industries (only outperformed by the oil and gas industry), the phar-
maceutical industry ranks only eleventh when intangible assets are taken into
account. CONCLUSIONS: Our analysis shows that pharmaceutical profits are bi-
ased upwards due to measurement errors of conventional accounting measures.
Against this background it is questionable if further price cuts of pharmaceuticals
are a good measure of reigning in the exploding health bill.
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OBJECTIVES: The aim of this study was to evaluate how national pricing and reim-
bursement processes are affecting medicines’ time-to-market (defined as the delay
in days between regulatory approval and market launch) and how their evolution
over the last 10 years has influenced launch sequences across a sample of 18
developed and emerging markets. METHODS: For each market discussed, national
pricing and reimbursement processes were studied through primary and second-
ary research. In each market, these processes were considered from a public versus
private sector perspective and from a primary versus secondary-care segment per-
spective. Meanwhile, to assess evolving launch sequencing trends, time-to-market
data were collected in each of the discussed markets for 16 medicines approved for
commercialisation between 2000 and 2010. RESULTS: Medicine launch occurs
within weeks of regulatory approval in free-pricing countries and upon completion
of pricing and reimbursement negotiations in countries where either the public or
both the public and private markets are price-controlled. Pharmaceutical launch
sequences have evolved over the last 10 years, both from a geographic and tempo-
ral perspective. Based on our sample of medicines, the time gap between first and
second international launch has narrowed from an average of 276 days in 2000 to
an average of 57 days in 2010. Primary-care medicines reach the market faster and
in a greater number of countries than secondary-care medicines. Secondary-care
medicines remain preferentially commercialised in mature, top-tiers markets un-
less they meet a medical need in emerging markets. CONCLUSIONS: A Medicine’s
time-to-market varies from country to country and broadly reflects the level of
complexity and differentiation of national pricing and reimbursement processes.
However, additional factors also come into play, including the level of innovation
of the medicine, the national medical need for the medicine, the sector (public
versus private) and segment (primary versus secondary care) targeted, and the
corporate strategy.
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